Evaluating Precision of Therapy - Milrinone
Launched by THE HOSPITAL FOR SICK CHILDREN · Apr 23, 2013
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
The proposed trial is a pilot of an open label, randomized trial of milrinone therapeutic drug monitoring in patients \< 18 years treated with milrinone following open-heart surgery for congenital heart disease at the Hospital for Sick Children, Toronto. We will randomize patients to (1) receiving therapeutic drug monitoring or (2) control patients who receive standard care. Standard care involves titration of milrinone infusion based on clinical examination by the treating team. Control patients will have milrinone plasma levels drawn but not analysed until the end of the study. The interv...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admitted to a Pediatric (0 - 18 years) Intensive Care Unit following cardiopulmonary bypass (CPB) and surgery for congenital heart disease.
- • Clinical decision by treating team to start milrinone infusion.
- • Anticipated to receive milrinone infusion for more than 24hs. This limit will increase the proportion of sicker children in the sample, increasing the power of the study.
- • Has an arterial line, and a central venous line defined as radiologically confirmed line
- • Informed consent obtained
- Exclusion Criteria:
- • Premature infants (\<36 weeks post-conceptual age) or weight less than 2.0 kg.
- • Failure to provide consent
About The Hospital For Sick Children
The Hospital for Sick Children (SickKids) is a leading pediatric health care and research institution located in Toronto, Canada. With a commitment to advancing child health through innovative research, education, and clinical care, SickKids is recognized globally for its expertise in pediatric medicine. The hospital actively sponsors clinical trials aimed at improving treatment outcomes and enhancing the quality of life for children with various health conditions. By fostering collaboration among multidisciplinary teams and leveraging state-of-the-art facilities, SickKids strives to translate research findings into tangible advancements in pediatric care, ensuring that children receive the best possible treatments based on the latest scientific evidence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Patients applied
Trial Officials
Katherine Taylor, MD
Principal Investigator
The Hospital for Sick Children
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials